Daily Journal masthead

Strong US dollar hurts Swiss pharmaceutical company Novartis with 32-percent drop in Q2 profit


BERLIN — Swiss-based pharmaceutical giant Novartis' second-quarter net income dropped 32 percent over the same quarter last year, brought down primarily by poor performance from associated companies and negative effects of a strong U.S. dollar, the company said Tuesday

Net income was $1.856 billion, down from $2.723 billion in the same quarter in 2014. Net sales were down 5 percent to $12.694 billion and earnings per share from continuing operations dropped to $0.77 from $1.11 last year.

Nevertheless, CEO Joseph Jimenez said the company had a strong quarter for innovation with the U.S. approval and launch of two new drug products — heart failure drug Entresto and multiple sclerosis therapy drug Glatopa — and confirmed its full-year guidance.

Group sales are expected to grow by mid-single digits and operating income is expected to grow ahead of sales at a high-single-digit rate, Novartis has said.

"We are confident we will deliver on our priorities for the year," Jimenez said.

Novartis said its core group's net income was down 8 percent to $3.074 billion but would have been up 5 percent in constant currencies.

If the U.S. dollar maintains its mid-July strength for the rest of the year, it will contribute to a 9 percent drop in sales and 13-14 percent on core operating income, the company said.

Think your friends should see this? Share it with them!

Story copyright 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Feedback, Corrections and Other Requests: AP welcomes feedback and comments from readers. Send an email to info@ap.org and it will be forwarded to the appropriate editor or reporter.

We also have more stories about:
(click the phrases to see a list)


Follow Daily Journal:

All content copyright ©2015 Daily Journal, a division of Home News Enterprises unless otherwise noted.
All rights reserved. Privacy policy.